264 related articles for article (PubMed ID: 35776322)
1. Development of Antibody and Nanobody Tools for P2X7.
Stähler T; Danquah W; Demeules M; Gondé H; Hardet R; Haag F; Adriouch S; Koch-Nolte F; Menzel S
Methods Mol Biol; 2022; 2510():99-127. PubMed ID: 35776322
[TBL] [Abstract][Full Text] [Related]
2. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.
Bannas P; Hambach J; Koch-Nolte F
Front Immunol; 2017; 8():1603. PubMed ID: 29213270
[TBL] [Abstract][Full Text] [Related]
3. Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation.
Danquah W; Meyer-Schwesinger C; Rissiek B; Pinto C; Serracant-Prat A; Amadi M; Iacenda D; Knop JH; Hammel A; Bergmann P; Schwarz N; Assunção J; Rotthier W; Haag F; Tolosa E; Bannas P; Boué-Grabot E; Magnus T; Laeremans T; Stortelers C; Koch-Nolte F
Sci Transl Med; 2016 Nov; 8(366):366ra162. PubMed ID: 27881823
[TBL] [Abstract][Full Text] [Related]
4. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2553. PubMed ID: 30524421
[TBL] [Abstract][Full Text] [Related]
5. A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7
Gondé H; Demeules M; Hardet R; Scarpitta A; Junge M; Pinto-Espinoza C; Varin R; Koch-Nolte F; Boyer O; Adriouch S
Front Immunol; 2021; 12():704408. PubMed ID: 34489954
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies as probes to investigate purinergic signaling.
Eggers M; Rühl F; Haag F; Koch-Nolte F
Biochem Pharmacol; 2021 May; 187():114394. PubMed ID: 33388283
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Transduction of P2X7-Expressing Cells with Recombinant rAAV Vectors.
Mann AM; Schäfer W; Adriouch S; Börner K; Grimm D; Braren I; Koch-Nolte F
Methods Mol Biol; 2022; 2510():129-144. PubMed ID: 35776323
[TBL] [Abstract][Full Text] [Related]
8. Introduction to heavy chain antibodies and derived Nanobodies.
Vincke C; Muyldermans S
Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
[TBL] [Abstract][Full Text] [Related]
9. Applications of nanobodies in plant science and biotechnology.
Wang W; Yuan J; Jiang C
Plant Mol Biol; 2021 Jan; 105(1-2):43-53. PubMed ID: 33037986
[TBL] [Abstract][Full Text] [Related]
10. Novel biologics targeting the P2X7 ion channel.
Koch-Nolte F; Eichhoff A; Pinto-Espinoza C; Schwarz N; Schäfer T; Menzel S; Haag F; Demeules M; Gondé H; Adriouch S
Curr Opin Pharmacol; 2019 Aug; 47():110-118. PubMed ID: 30986625
[TBL] [Abstract][Full Text] [Related]
11. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
12. Nanobody-Based Biologics for Modulating Purinergic Signaling in Inflammation and Immunity.
Menzel S; Schwarz N; Haag F; Koch-Nolte F
Front Pharmacol; 2018; 9():266. PubMed ID: 29636685
[TBL] [Abstract][Full Text] [Related]
13. Generation, expression and utilization of single-domain antibodies for in vivo protein localization and manipulation in sea urchin embryos.
Schrankel CS; Gökirmak T; Lee CW; Chang G; Hamdoun A
Methods Cell Biol; 2019; 151():353-376. PubMed ID: 30948018
[TBL] [Abstract][Full Text] [Related]
14. Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma.
Bannas P; Koch-Nolte F
Front Immunol; 2018; 9():2559. PubMed ID: 30459772
[TBL] [Abstract][Full Text] [Related]
15. Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools.
Liu B; Yang D
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163405
[TBL] [Abstract][Full Text] [Related]
16. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins.
Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano).
Demeules M; Scarpitta A; Abad C; Gondé H; Hardet R; Pinto-Espinoza C; Eichhoff AM; Schäfer W; Haag F; Koch-Nolte F; Adriouch S
Front Oncol; 2020; 10():1699. PubMed ID: 33042812
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of nanobody sequence and structure data.
Mitchell LS; Colwell LJ
Proteins; 2018 Jul; 86(7):697-706. PubMed ID: 29569425
[TBL] [Abstract][Full Text] [Related]
19. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
[TBL] [Abstract][Full Text] [Related]
20. Nanobodies: From Serendipitous Discovery of Heavy Chain-Only Antibodies in Camelids to a Wide Range of Useful Applications.
Ji F; Ren J; Vincke C; Jia L; Muyldermans S
Methods Mol Biol; 2022; 2446():3-17. PubMed ID: 35157266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
